BioNTech presents early data on BNT211; inks deal with Matinas

Confirming it has a lot more to offer than just the highly successful COVID-19 vaccine Comirnaty, Germany’s BioNTech (Nasdaq: BNTX) has presented data from its ongoing first-in-human Phase I/II trial evaluating the safety and preliminary efficacy of the company’s novel CAR-T cell therapy candidate, BNT211, in patients with advanced solid tumors.

The preliminary results demonstrated an encouraging safety profile and anti-tumor activity in testicular cancer patients at the first evaluated dose levels of BNT211. The data were presented in the Clinical Trials Plenary Session at the AACR Annual Meeting 2022 by Prof John Haanen, Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.

BNT211 is a potential first-in-class therapeutic approach which comprises two drug products, an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac), which is based on BioNTech’s mRNA-lipoplex technology to improve persistence and functionality of the adoptively transferred cells.